查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863032

感染疾病药物市场按药物类别、给药途径、适应症、通路和最终用户划分－2025年至2032年全球预测

Infectious Disease Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，感染疾病治疗市场规模将达到 1,731.3 亿美元，复合年增长率为 4.55%。

关键市场统计数据
基准年 2024 1212.7亿美元
预计年份：2025年 1268亿美元
预测年份 2032 1731.3亿美元
复合年增长率 (%) 4.55%

针对感染疾病药物领域的简明策略框架，能够使相关人员在临床创新、监管趋势和营运重点方面达成共识。

感染疾病治疗领域正处于关键转折点，这主要得益于分子生物学的进步、疫苗研发进程的加速以及日益复杂的全球供应链环境。本导言为研究、生产、临床实践和政策等各相关人员提供了策略背景，重点阐述了科学创新与监管合规的融合将如何影响近期决策。我们确立了贯穿整份报告的分析观点：一种将治疗方法、给药途径和最终用户实际情况与营运限制和商业性机会联繫起来的综合视角。

后续章节将评估市场动态，探讨政策动因和细分市场的具体影响，并将这些因素整合起来，提出优先行动指南。本文重点在于转化视角：研发管线中的创新成果如何从实验室走向临床，生产韧性如何影响产品供应，以及通路如何影响病患在医疗服务点的取得。透过整合技术、监管和商业性因素，本导论为读者理解后续章节做好准备，并着重阐述对投资、伙伴关係和营运规划的实际意义。

技术创新、监管现代化和不断变化的临床需求正在重新定义感染疾病药物的研发路径和商业化策略。

感染疾病药物领域正经历着变革性的转变，这得益于技术突破、新的监管模式以及临床需求的转变。基因疗法和生物疗法日益成熟，单株抗体和细胞激素调节剂不仅成为治疗工具，更成为综合治疗方法的重要组成部分。同时，能够实现快速设计、迭代改进和适应性生产的疫苗技术平台正在重塑针对不同病原体的预防策略。这些技术发展伴随着数位和诊断技术的进步，使得早期检测和更有针对性的治疗选择成为可能，从而改变了临床路径和支付方的考量。

除了科学层面，监管机构正在采用更灵活的审查机制和紧急使用框架。这些措施加快了产品准入速度，同时要求申办方致力于更持续的上市后证据收集。因此，商业化策略越来越注重生命週期规划，力求在加速市场进入和强而有力的真实世界证据项目之间取得平衡。同时，医疗系统正在修订采购政策和药品目录，优先考虑那些不仅具有临床疗效，而且供应稳定可靠、价格合理的药品。总而言之，这些变化要求企业重组其研发开发平臺、製造地和市场进入策略，以保持竞争力并满足快速变化的临床需求。

对 2025 年关税趋势对治疗领域供应链策略、采购决策和在地化生产的影响进行全面分析。

2025年美国关税政策的累积影响正在重塑整个感染疾病治疗生态系统的供应链经济、采购行为和策略采购决策。关税变化直接影响了原料药、某些生物製药以及商业生产和研发所必需的试剂的成本。由此带来的单位经济效益压力正促使製造商重新考虑供应商多元化、库存持有策略以及近岸外包方案，以降低进口相关成本波动带来的风险。

为因应这项挑战，具有前瞻性的企业正在加速投资本地生产能力，并与合约研发生产机构（CDMO）建立策略联盟，以增强区域韧性。这些措施旨在保护生产免受关税导致的利润率下降的影响，同时确保高优先级产品能够快速上市。此外，采购部门正在采取更精细的成本控制措施，重新谈判长期合同，并采用总落地成本分析，而不仅仅是单位成本分析。监管机构和医保报销相关人员也出现了类似的趋势。支付者正在更密切地审查成本驱动因素，医疗系统正在将供应链风险评估纳入药品目录编制决策中。

最后，关税环境凸显了政策参与的重要性。产业相关人员正积极解释贸易措施对临床实践和公共卫生的下游影响，并努力推动调整，以确保患者获得治疗并维持生产竞争力。整体而言，2025 年的关税环境不仅导致成本负担的重​​新分配，也推动了整个治疗价值链中采购、生产策略和相关人员合作的结构性变革。

透过对治疗领域、给药途径、临床适应症、通路和终端用户趋势进行综合观点，明确优先顺序。

细分市场分析揭示了产品、剂量和临床应用的差异，从根本上改变了药物研发和商业化策略。从抗生素、抗真菌药物、抗病毒药、生物製药和疫苗等药物类别来看，每一类都存在独特的临床和生产方面的考量。抗生素在包括Aminoglycosides、β-内酰胺类、Fluoroquinolones、大环内酯类和四环霉素在内的各种亚类中仍然非常重要，每种抗生素都有其独特的抗药性动态和用药管理要求，这些都会影响临床指南和采购政策。抗真菌药物（包括Azole、Echinocandins和Polyenes）在诊断和剂量复杂性方面面临独特的挑战，这些挑战影响医院处方集的采纳和门诊治疗路径。抗病毒药物，包括整合酶抑制剂、神经氨酸酶抑制剂、核苷类似物和蛋白酶抑制剂，具有治疗特异性和抗药性特征，这些特征推动了联合用药策略和依从性干预措施的发展。

生物製药，包括细胞激素和单株抗体，需要复杂的低温运输物流和生产控制策略，这与小分子药物截然不同。同时，结合疫苗、灭活疫苗、减毒活病毒疫苗和次单位疫苗等疫苗类型也需要独特的生产设施、低温运输要求和监管文件。给药途径是关键的细分维度：吸入、静脉注射、口服和局部用药会影响病患依从性、临床经济性和分销管道的适用性。按适应症进行细分可以进一步优化策略选择。不同的治疗领域，例如 COVID-19、胃肠道感染疾病、肝炎、HIV/AIDS、呼吸道感染疾病、皮肤感染疾病和尿道感染感染，分别驱动着不同的临床试验设计、真实世界证据需求和与支付者的互动。分销管道的差异——医院药房、线上药房和零售药房——塑造供应模式和上市后监测路径。同时，最终用户细分（诊所、居家医疗和医院）决定了服务交付模式、容量规划和支援服务需求。

整合这些细分维度，能够帮助相关人员识别：未满足的临床需求与有利的产品属性相交的领域、生产复杂性与报销潜力相交的领域，以及给药途径创新能够开闢新途径的领域。这种整合的细分观点有助于更精准地确定投资组合的优先顺序、更有针对性地与临床和支付相关利益者互动，以及製定能够反映具体应用场景实际情况的最佳化分销策略。

美洲、欧洲、中东和非洲以及亚太地区的区域监管差异、生产能力和医疗保健系统优先事项将如何决定医疗服务的可近性和策略重点？

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的监管时间表、生产策略和病患用药途径有重大影响。在美洲，法规环境各不相同，从核准途径严格的高度集中体係到可能延缓跨境用药的分散式司法管辖结构，不一而足。这种多样性要求制定差异化的市场进入策略、策略定价方案以及保障供应连续性的紧急时应对计画。在欧洲、中东和非洲地区，相关人员必须应对复杂的监管方法、报销框架和公共卫生优先事项。在此，联合采购机制和区域疾病负担在产品推广和公开竞标中发挥关键作用。

亚太地区拥有成熟市场和快速发展市场并存的多元化格局，多个经济体具备强大的本地製造能力，对先进生物製药和价格适中的小分子药物的需求日益增长。该地区的政策驱动因素通常优先考虑关键药物的自给自足，鼓励对国内生产和技术转移进行投资。不同地区的医疗体系资金筹措机制、公共卫生优先事项和物流限制各不相同，这决定了对低温运输基础设施、照护现场诊断和分散式供应模式的投资在哪些地区能够发挥最大作用。重要的是，区域监管协调工作和多边采购倡议有望降低创新治疗方法的进入门槛，前提是申办方能够调整其申请和证据产生策略，以满足多个司法管辖区的要求。

感染疾病治疗领域的成功驱动因素是科学差异化、生产策略和伙伴关係模式的竞争格局。

感染疾病治疗领域中主要企业之间的竞争动态是由科学差异化、生产规模和伙伴关係弹性三者共同驱动的。成熟的跨国公司继续利用其丰富的研发管线和全球生产网络，支持后期研发和大规模商业性化上市。同时，规模较小的生技公司则倾向于专注于独特的作用机製或可授权或合作开发的平台技术。合约研发生产机构（CDMO）作为策略推动者，提供灵活的产能和生物製药及疫苗生产方面的专业知识，从而帮助缺乏固定生产资产的申办方加快临床试验的启动。

纵观整个产业格局，成功的企业正在采用多种经营模式的组合。有些企业优先考虑对生产进行垂直整合控制，以确保供应链的稳定性；而有些企业则采取轻资产模式，透过外部伙伴关係强调速度和产品组合的广度。从用于药物警戒的高级分析到远端患者监护和用药依从性平台，数位技术正被越来越多地用于差异化商业性提案并支持与支付方的互动。治疗药物开发商、诊断公司和分销合作伙伴之间的策略联盟也日益普遍，这反映出人们认识到，整合解决方案可以改善临床结果并简化医疗系统的采购流程。总而言之，那些兼具科学严谨性、营运适应性和协作式市场推广策略的企业正在竞争激烈的市场环境中占据优势。

为产业领导者提供切实可行的优先行动方案，以加强其治疗产品组合的供应韧性、证据产生和以患者为中心的市场进入。

产业领导者应采取优先且切实可行的措施，以应对不断变化的科学、监管和供应链现实。首先，企业应将供应链韧性作为核心策略目标，具体措施包括供应商多元化、寻求区域性生产方案以及建立紧急库存体系。这些措施将有助于降低贸易政策波动带来的风险，并确保医疗服务的连续性。其次，将真实世界证据的生成融入产品上市及上市后活动中，将有助于加快支付方的接受度，并支持灵活的监管路径。为此，各机构应投资于数位资料收集工具和跨相关人员的证据合作，以确保获得高品质的长期结果数据。

第三，商业策略必须日益重视给药途径和终端使用者偏好。开发以患者为中心的製剂和给药方案，支持居家医疗和门诊护理，可以转变用药模式，使患者和支付方都从中受益。第四，应积极寻求与契约製造、诊断公司和区域经销商建立策略联盟，以应对产能限制并简化市场进入。最后，企业应优先与政策制定者和采购机构进行透明对话，沟通临床价值以及贸易和关税政策对市场准入的影响。全面实施这些措施，将有助于平衡短期业务需求与长期价值创造和市场韧性。

采用透明的多方法研究途径，结合专家访谈、二手证据检验验证和检验程序，确保研究结果具有可操作性和可重复性。

本分析的调查方法结合了多源证据综合、专家访谈以及严格的检验通讯协定，以确保研究结果的稳健性和相关性。主要资料来源包括对临床医生、供应链高管、监管专家和商业领袖的结构化访谈，旨在收集关于临床实践、采购决策和生产策略的一线观点。这些质性研究结果与包括同侪审查的临床文献、已发布的监管指导文件和公司检验在内的二手资料进行三角验证，从而建立起基于事实的治疗方法特征和监管趋势的基础。

为确保分析的严谨性，研究结果透过与专家和技术负责人的反覆咨询进行交叉检验，这些专家和技术审查人员评估了有关临床实施、生产复杂性和分销物流的假设。数据品管包括资讯来源核实、对受访者进行利益衝突筛检，以及记录如何将一手和二手资讯纳入分析结论的审核追踪。方法论强调透明度和可重复性，详细的附录包括访谈通讯协定、二级资讯来源选择标准和细分轴定义，使读者能够评估策略建议的依据，并将这些见解应用于自身的营运环境。

整合以韧性、实证市场进入和营运诚信为核心的策略要务，以推动技术应用并改善病患疗效。

总之，感染疾病治疗领域正受到多种因素的共同影响而重塑：快速的科学创新、不断变化的监管要求以及受关税调整等政策变化影响的供应链现状。这些趋势对价值链上的相关人员——包括研发人员、製造商、支付者和医疗保健系统——提出了挑战，要求他们采取整合策略，将科学差异化与营运韧性相结合。本报告提出的细分框架阐明了治疗特性、给药途径、临床适应症和分销管道的交汇点，从而形成了独特的策略要务。

成功的组织能够将技术创新转化为可扩展的生产和供应模式，同时保持灵活且基于实证的市场进入策略。与监管机构和采购相关人员积极合作、对製造和数据基础设施进行有针对性的投资以及创造性的伙伴关係模式，对于保持竞争优势至关重要。本文提出的综合分析旨在透过强调在降低风险、加速技术应用和改善患者预后等方面，如何最有效地利用资源和资金，从而支持明智的决策，并涵盖各种感染疾病防治重点领域。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 加速研发基于mRNA的疫苗，用于预防季节性和新出现的呼吸道病毒
  • 越来越多的免疫力缺乏新冠肺炎患者开始接受长效单株抗体预防治疗。
  • 在三级医疗机构中整合基于 CRISPR 的快速诊断和个人化抗生素管理
  • 频谱病毒聚合酵素抑制剂在控制流行性呼吸道病原体方面的临床进展
  • 口服直接抗病毒药物的出现，针对慢性D型肝炎肝炎病毒感染，为治疗慢性B型肝炎提供了新的思路。
  • 生物导向疗法的创新：调节先天免疫和降低败血症相关死亡率
  • 在临床试验中设计合成抗菌肽以对抗多重抗药性细菌感染疾病

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章感染疾病药物市场（依药物类别划分）

  • 抗生素
    • Aminoglycosides
    • β-内酰胺类
    • Fluoroquinolones
    • 大环内酯类
    • 四环霉素
  • 抗真菌药物
    • Azole
    • Echinocandins
    • Polyenes
  • 抗病毒药物
    • 整合酶抑制剂
    • 神经氨酸酶抑制剂
    • 核苷类似物
    • 蛋白酶抑制剂
  • 生物製药
    • 细胞激素
    • 单株抗体
  • 疫苗
    • 组合型
    • 失活
    • 活病毒疫苗
    • 次单元

第九章感染疾病药物市场（依给药途径划分）

  • 吸入
  • 静脉注射
  • 口服
  • 局部用药

第十章感染疾病药物市场（依适应症划分）

  • COVID-19
  • 胃肠道感染疾病
  • 肝炎
  • 爱滋病毒/爱滋病
  • 呼吸道感染疾病
  • 皮肤感染疾病
  • 尿道感染

第十一章感染疾病药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章感染疾病药物市场（依最终用户划分）

  • 诊所
  • 居家医疗
  • 医院

第十三章 各地区感染疾病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章感染疾病药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国感染疾病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • AstraZeneca plc
    • AbbVie Inc.
    • Novartis AG
Product Code: MRR-F6513A06BE17

The Infectious Disease Therapeutics Market is projected to grow by USD 173.13 billion at a CAGR of 4.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 121.27 billion
Estimated Year [2025] USD 126.80 billion
Forecast Year [2032] USD 173.13 billion
CAGR (%) 4.55%

Concise strategic framing of the infectious disease therapeutics environment to orient stakeholders around clinical innovation, regulatory dynamics, and operational priorities

The infectious disease therapeutics landscape is at a pivotal inflection point driven by advances in molecular biology, accelerated vaccine development pathways, and an increasingly complex global supply environment. This introduction frames the strategic context for stakeholders across research, manufacturing, clinical practice, and policy, emphasizing the confluence of scientific innovation and regulatory adaptation that shapes near-term decisions. It establishes the analytical lens used throughout this report: an integrated view that links therapeutic modality, route of administration, and end-user realities to operational constraints and commercial opportunity.

In the following sections, the reader will encounter assessments of market dynamics, policy shocks, and segmentation-specific implications that collectively inform high-priority actions. The narrative prioritizes translational considerations: how pipeline innovations move from lab to clinic, how manufacturing resilience influences product availability, and how distribution channels modulate access at the point of care. By synthesizing technical, regulatory, and commercial vectors, this introduction prepares the reader to interpret downstream chapters with a focus on practical implications for investment, partnership, and operational planning.

How converging technological advances, regulatory modernization, and shifting clinical demand are redefining development pathways and commercialization strategies for infectious disease therapies

Transformative shifts in infectious disease therapeutics are unfolding through technological breakthroughs, novel regulatory paradigms, and shifting patterns of clinical demand. Gene-based and biologic approaches have matured to the point where monoclonal antibodies and cytokine modulators are not only therapeutic tools but also essential components of integrated treatment regimens. Concurrently, vaccine technology platforms that enable rapid design, iterative improvements, and adaptive manufacturing are reshaping prevention strategies across diverse pathogen classes. These technical developments are accompanied by digital and diagnostic advances that allow for earlier detection and more targeted therapy selection, thereby altering clinical pathways and payer considerations.

Beyond science, regulatory agencies have adopted more flexible review mechanisms and emergency-use frameworks that, while expediting access, require sponsors to engage in more continuous post-market evidence generation. As a result, commercialization strategies increasingly require lifecycle planning that balances accelerated entry with robust real-world evidence programs. In parallel, health systems are recalibrating procurement and formularies to favor products that demonstrate not only clinical efficacy but also demonstrable supply resilience and affordability. Taken together, these shifts demand that companies re-architect R&D pipelines, manufacturing footprints, and market access approaches to remain competitive and responsive to rapidly evolving clinical needs.

Comprehensive analysis of how 2025 tariff developments are recalibrating supply chain strategies, procurement decisions, and manufacturing localization across therapeutics

The cumulative effects of United States tariff policy developments in 2025 are shaping supply-chain economics, procurement behaviors, and strategic sourcing decisions across the infectious disease therapeutics ecosystem. Tariff changes have had a direct bearing on the cost of active pharmaceutical ingredients, certain biologics inputs, and reagents critical to both commercial manufacturing and research operations. The resulting pressure on unit economics has compelled manufacturers to revisit supplier diversification, inventory stocking policies, and nearshoring alternatives to mitigate exposure to import-related cost volatility.

In response, forward-looking organizations have accelerated investments in localized manufacturing capabilities and strategic partnerships with contract development and manufacturing organizations that offer regional resiliency. These moves are intended to insulate production from tariff-induced margin erosion while preserving speed-to-market for high-priority products. Additionally, procurement teams have adopted more granular cost-control measures, renegotiating long-term contracts and applying total landed cost analysis rather than price-per-unit alone. Regulatory and reimbursement stakeholders have likewise taken notice: payers are scrutinizing cost drivers more closely, and health systems are incorporating supply-chain risk assessments into formulary decisions.

Finally, the tariff environment has amplified the importance of policy engagement. Industry participants are increasingly proactive in articulating the downstream clinical and public-health implications of trade measures, aiming to inform adjustments that preserve patient access and maintain manufacturing competitiveness. Overall, the 2025 tariff context has not only reallocated cost burdens but also catalyzed structural shifts in sourcing, manufacturing strategy, and stakeholder alignment across the therapeutic value chain.

Integrated segmentation perspective connecting therapeutic class, administration route, clinical indication, distribution channel, and end-user dynamics to inform prioritization

Segmentation analysis illuminates product, administration, and clinical-use distinctions that fundamentally alter development and commercialization approaches. When viewed through drug class lenses such as antibiotics, antifungals, antivirals, biologics, and vaccines, each category presents unique clinical and manufacturing considerations. Antibiotics retain importance across diverse sub-classes including aminoglycosides, beta-lactams, fluoroquinolones, macrolides, and tetracyclines, each with differing resistance dynamics and stewardship imperatives that influence clinical guidelines and procurement preferences. Antifungal therapies, encompassing azoles, echinocandins, and polyenes, face distinct diagnostics and dosing complexities that shape hospital formulary uptake and outpatient treatment pathways. Antiviral agents such as integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors exhibit therapeutic specificity and resistance profiles that drive combination strategies and adherence interventions.

Biologics, including cytokines and monoclonal antibodies, require sophisticated cold-chain logistics and manufacturing control strategies that differentiate them from small-molecule agents, while vaccine types such as conjugate, inactivated, live attenuated, and subunit platforms each demand tailored manufacturing footprints, cold-chain requirements, and regulatory dossiers. Route of administration is a pivotal segmentation axis: inhalation, intravenous, oral, and topical modalities affect patient adherence, site-of-care economics, and distribution channel suitability. Indication-specific segmentation further refines strategic choices; therapeutic focus areas such as COVID-19, gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections create distinct clinical trial designs, real-world evidence needs, and payer conversations. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy shape fulfillment models and post-market surveillance pathways, while end-user segmentation - clinics, homecare, and hospitals - determines service delivery models, capacity planning, and support-service requirements.

Bringing these segmentation dimensions together enables stakeholders to identify where clinical unmet needs intersect with advantageous product characteristics, where manufacturing complexity aligns with reimbursement potential, and where route-of-administration innovations can unlock new access pathways. This integrated segmentation perspective supports more precise prioritization of portfolio investments, targeted engagement with clinical and payer stakeholders, and optimized distribution strategies that reflect distinct use-case realities.

How regional regulatory diversity, manufacturing capacity, and health-system priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific determine access and strategic focus

Regional dynamics exert a material influence on regulatory timelines, manufacturing strategy, and patient access across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, regulatory environments vary from highly centralized systems with robust approval pathways to fragmented jurisdictional landscapes that can slow cross-border access; this diversity necessitates differentiated market-entry tactics, strategic pricing discussions, and contingency plans for supply continuity. In the Europe Middle East & Africa context, stakeholders must navigate a mosaic of regulatory approaches, reimbursement frameworks, and public-health priorities, where collaborative procurement mechanisms and regional disease burden profiles play a significant role in adoption curves and public tenders.

Asia-Pacific presents a dynamic mix of established and rapidly evolving markets, with strong local manufacturing capacity in several economies and growing demand for both advanced biologics and accessible small-molecule therapies. Policy drivers in this region often prioritize self-reliance in critical medicines, fostering investment in domestic production and technology transfer. Across regions, differences in health-system funding mechanisms, public-health priorities, and logistical constraints shape where investment in cold-chain infrastructure, point-of-care diagnostics, and decentralized delivery models will yield the greatest returns. Importantly, regional regulatory harmonization efforts and multilateral procurement initiatives have the potential to lower barriers to entry for innovative therapies, provided that sponsors align dossiers and evidence-generation strategies to meet cross-jurisdictional requirements.

Key competitive patterns revealing how scientific differentiation, manufacturing strategy, and partnership models drive success in infectious disease therapeutics

Competitive dynamics among leading companies in infectious disease therapeutics are driven by a combination of scientific differentiation, manufacturing scale, and partnership agility. Established multinational firms continue to leverage deep pipelines and global manufacturing networks to support late-stage development and broad commercial launches, while smaller biotechnology companies often focus on niche mechanisms of action or platform technologies that can be licensed or co-developed. Contract development and manufacturing organizations have become strategic enablers, offering flexibility in capacity and specialized know-how for biologic and vaccine production, which accelerates time-to-clinic for sponsors without fixed manufacturing assets.

Across the landscape, successful companies deploy a mix of business models: some prioritize vertically integrated control over manufacturing to ensure supply resilience, while others pursue asset-light approaches that emphasize speed and portfolio breadth through external partnerships. Digital capabilities-ranging from advanced analytics for pharmacovigilance to remote patient monitoring and adherence platforms-are increasingly used to differentiate commercial propositions and support payer dialogues. Strategic alliances between therapeutic developers, diagnostic firms, and distribution partners are also more common, reflecting a recognition that bundled solutions can improve clinical outcomes and simplify procurement for health systems. In sum, the competitive landscape rewards organizations that combine scientific rigor with operational adaptability and collaborative go-to-market strategies.

Practical high-priority actions for industry leaders to strengthen supply resilience, evidence generation, and patient-centric market access across therapeutic portfolios

Industry leaders should adopt a set of prioritized, actionable measures to navigate evolving scientific, regulatory, and supply-chain realities. First, companies must embed supply resilience as a core strategic objective by diversifying supplier bases, pursuing regional manufacturing options, and formalizing contingency inventories; such measures reduce exposure to trade-policy shocks and maintain continuity of care. Second, integrating real-world evidence generation into launch and post-marketing activities will accelerate payer acceptance and support adaptive regulatory pathways, so organizations should invest in digital data capture tools and cross-stakeholder evidence partnerships to ensure high-quality, longitudinal outcome data.

Third, commercial strategies must increasingly account for route-of-administration and end-user preferences; developing patient-centric formulations or delivery options that enable homecare and outpatient treatment can shift utilization patterns in a way that benefits both patients and payers. Fourth, strategic partnerships with contract manufacturers, diagnostics firms, and regional distributors should be pursued proactively to manage capacity constraints and streamline market access. Finally, companies should prioritize transparent engagement with policymakers and procurement bodies to communicate clinical value and the implications of trade or tariff policies on access. Collectively, these actions balance short-term operational imperatives with long-term value creation and resilience.

Transparent multi-method research approach combining expert interviews, secondary evidence triangulation, and validation procedures to ensure actionable and reproducible insights

The research methodology underpinning this analysis combined multi-source evidence synthesis, targeted expert engagement, and rigorous validation protocols to ensure robustness and relevance. Primary inputs included structured interviews with clinicians, supply-chain executives, regulatory specialists, and commercial leaders to capture first-hand perspectives on clinical practice, procurement decision-making, and manufacturing strategy. These qualitative insights were triangulated with secondary source materials such as peer-reviewed clinical literature, publicly available regulatory guidance documents, and company disclosures to establish a factual baseline for therapeutic modality characteristics and regulatory trends.

To ensure analytical rigor, findings were cross-validated through iterative consultations with subject-matter experts and technical reviewers who assessed assumptions about clinical adoption, manufacturing complexity, and distribution logistics. Data quality controls included source provenance checks, conflict-of-interest screening for interview participants, and an audit trail documenting how primary and secondary inputs informed each analytical conclusion. The methodology emphasizes transparency and reproducibility; detailed appendices provide interview protocols, inclusion criteria for secondary sources, and definitions for segmentation axes so that readers can evaluate the basis for strategic recommendations and adapt insights to their own operational contexts.

Synthesis of strategic imperatives emphasizing resilience, evidence-driven market access, and operational alignment to accelerate adoption and improve patient outcomes

In conclusion, infectious disease therapeutics are being reshaped by intersecting forces: rapid scientific innovation, evolving regulatory expectations, and supply-chain realities intensified by policy shifts such as tariff adjustments. These dynamics demand that stakeholders across the value chain-developers, manufacturers, payers, and health systems-adopt integrated strategies that align scientific differentiation with operational resilience. The segmentation framework presented in this report clarifies where therapeutic characteristics, administration routes, clinical indications, and distribution channels converge to create distinct strategic imperatives.

Looking ahead, success will favor organizations that can translate technical innovations into scalable production and delivery models while maintaining flexible, evidence-driven approaches to market access. Proactive engagement with regulatory and procurement stakeholders, targeted investments in manufacturing and data infrastructure, and creative partnership models will be central to sustaining competitive advantage. The synthesis provided here is intended to support informed decision-making by highlighting where effort and capital can most effectively reduce risk, accelerate adoption, and ultimately improve patient outcomes across diverse infectious disease priorities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Accelerated development of mRNA-based vaccines for seasonal and emerging respiratory virus prevention
  • 5.2. Increased adoption of long-acting monoclonal antibodies for prophylaxis in immunocompromised COVID-19 patients
  • 5.3. Integration of CRISPR-based rapid diagnostics with bespoke antibiotic stewardship in tertiary care hospitals
  • 5.4. Clinical advancement of broad-spectrum viral polymerase inhibitors for pandemic respiratory pathogen readiness
  • 5.5. Emergence of oral direct-acting antivirals targeting hepatitis delta co-infection in chronic hepatitis B regimes
  • 5.6. Innovation in host-directed therapies aiming to modulate innate immunity and reduce sepsis-related mortality
  • 5.7. Engineering synthetic antimicrobial peptides to overcome multidrug-resistant bacterial infections in clinical trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Disease Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antivirals
    • 8.3.1. Integrase Inhibitors
    • 8.3.2. Neuraminidase Inhibitors
    • 8.3.3. Nucleoside Analogues
    • 8.3.4. Protease Inhibitors
  • 8.4. Biologics
    • 8.4.1. Cytokines
    • 8.4.2. Monoclonal Antibodies
  • 8.5. Vaccines
    • 8.5.1. Conjugate
    • 8.5.2. Inactivated
    • 8.5.3. Live Attenuated
    • 8.5.4. Subunit

9. Infectious Disease Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Infectious Disease Therapeutics Market, by Indication

  • 10.1. COVID-19
  • 10.2. Gastrointestinal Infections
  • 10.3. Hepatitis
  • 10.4. HIV/AIDS
  • 10.5. Respiratory Infections
  • 10.6. Skin Infections
  • 10.7. Urinary Tract Infections

11. Infectious Disease Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Infectious Disease Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare
  • 12.3. Hospitals

13. Infectious Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Infectious Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Infectious Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Johnson & Johnson
    • 16.3.4. F. Hoffmann-La Roche Ltd
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. GlaxoSmithKline plc
    • 16.3.7. Sanofi S.A.
    • 16.3.8. AstraZeneca plc
    • 16.3.9. AbbVie Inc.
    • 16.3.10. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKE